AMGEN Inc
NASDAQ: AMGN
$281.55
-$14.38 (-4.9%)
Real Time Data Delayed 15 Min.
AMGN Articles
Tuesday’s top analyst upgrades, downgrades and initiations include Amgen, Dow Chemical, Fitbit, Office Depot, SanDisk, Wells Fargo and Yum! Brands.
Published:
Amgen has the potential to disrupt the market for cholesterol drugs with the newest addition to its drug portfolio.
Published:
The short interest data are out for the August 14 settlement date. Biotech companies are considered a riskier group of stocks.
Published:
The short interest data are out for the July 31 settlement date, and overall, short interest in the selected biotech stocks backed off for this period.
Published:
24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of August and added some color.
Published:
According to Argus, second-quarter earnings, along with a strong pipeline and general outlook, have positioned Amgen to take the market by storm.
Published:
ThinkstockAmgen Corp. (NASDAQ: AMGN) reported fiscal second quarter 2015 earnings Thursday afternoon after equity markets had closed. The biotech firm posted adjusted earnings per share (EPS) of...
Published:
Last Updated:
ThinkstockAmgen Inc. (NASDAQ: AMGN) is scheduled to report its earnings after the markets close on Thursday. There are consensus estimates from Thomson Reuters that call for $2.43 in earnings per...
Published:
ThinkstockThe short interest data are out for the July 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or break...
Published:
Last Updated:
ThinkstockPharmaceutical and Biotech investors are about to get a real show for earnings this week. Big Pharma will bring earnings from Dow Jones Industrial Average companies Merck & Co. Inc....
Published:
A new research report from Cowen focuses on the top biotech stocks to buy before second-quarter earnings are reported.
Published:
24/7 Wall St. has reviewed the short interest in top biotech companies, without focusing on speculative companies.
Published:
None of these stocks are on the momentum traders' radar, and that is exactly what prudent growth investors need now.
Published:
24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of July and added some color.
Published:
The short interest data are out for the June 15 settlement date, and overall, short interest in the selected biotech stocks was mixed.
Published: